Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.

Pharmacogenetics and genomics - 1 Nov 2017

Bousman Chad A, Jaksa Philip, Pantelis Christos

Abstract excerpt

OBJECTIVE: The aim of this study was to systematically assess commercial pharmacogenetic tests relevant to prescribing in psychiatry, with specific attention on CYP2D6 and CYP2C19 star allele coverage as well as compliance with consensus recommendations for pharmacogenetic test result reporting. MATERIALS AND METHODS: The CYP2D6 and CY2C19 star (*) allele contents of 20 pharmacogenetic test panels were compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP2D6

Share to Mental Disorders

Share to Pharmacogenetics

Share to Pharmacogenomic Testing

Share to Psychiatry

Source

Identifiers

PMID: 28777243
DOI: 10.1097/FPC.0000000000000303

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.PMID 28777243Read ↗

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19Semantic proximity Read ↗

CYP2D6 and CYP2C19 Variant Coverage of Commercial Antidepressant Pharmacogenomic Testing Panels Available in Victoria, AustraliaSemantic proximity Read ↗

Towards the implementation ofCYP2D6andCYP2C19genotypes in clinical practice: Update and report from a pharmacogenetic service clinicSemantic proximity Read ↗

A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources.Semantic proximity Read ↗

Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.Semantic proximity Read ↗

Pharmacogenetics in Psychiatry: An Update on Clinical UsabilitySemantic proximity Read ↗

The landscape of pharmacogenetic testing in a US managed care populationSemantic proximity Read ↗

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing PsychotropicsSemantic proximity Read ↗

Frequencies of CYP2C19 and CYP2D6 gene variants in a German inpatient sample with mood and anxiety disorders.Semantic proximity Read ↗

Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools.Semantic proximity Read ↗

Pharmacogenetic Testing: Time for Clinical Practice GuidelinesSemantic proximity Read ↗

Pharmacogenomic Insights in Psychiatric Care: Uncovering Novel Actionability, Allele-Specific CYP2D6 Copy Number Variation, and Phenoconversion in 15,000 PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.